Скачать или смотреть GLP-1 Price Cuts: What Lower Costs, Transparent Pricing, and Big Pharma Deals Mean for Patients

In this solo episode, Dr. Arti Thangudu breaks down the sweeping changes in GLP-1 medication pricing—and what these shifts truly mean for patients, clinicians, and the future of metabolic health. With new deals struck between the Trump administration, Eli Lilly, and Novo Nordisk, millions of Americans will soon gain access to medications like Zepbound and Wegovy at significantly lower prices. But behind the headlines lies a complex story of political strategy, pharmaceutical incentives, patient safety, and the ongoing dysfunction of the U.S. drug pricing system.

Arti offers a clear, compassionate, and candid look at how transparent cash pricing could finally bring competition—and lower costs—to the GLP-1 market, why patients must still be cautious about compounded versions, and why safe prescribing is more important than ever as access expands. This episode is a must-listen for anyone navigating metabolic health, obesity treatment, diabetes care, or the realities of a healthcare system undergoing rapid change.

----------
Key Topics Covered
The details behind the newly announced GLP-1 price reductions
What $245 Medicare pricing and $299–$499 cash-pay options mean for real patients
Why pharmaceutical companies benefit from transparent pricing—and why that still benefits patients
How transparent pricing may finally introduce price competition and drive costs down
The risks of compounded GLP-1s and why they’re not equivalent to brand-name medications
How the GLP-1 craze exposed the inner workings of PBMs, inflated list prices, and drug pricing dysfunction
Why safe, expert prescribing is essential as these drugs become widely accessible
The impact of social media, aesthetics-driven prescribing, and misuse of GLP-1s
The political strategy behind pharma–White House deals
The future of metabolic care as oral GLP-1s and broader access enter the market

----------
Who This Episode Is For
Patients using or considering GLP-1 medications
Individuals with obesity, diabetes, prediabetes, PCOS, fatty liver disease, or metabolic syndrome
Clinicians aiming to understand the evolving GLP-1 landscape
Employers and health plan leaders evaluating future coverage
Anyone interested in drug pricing, PBMs, or healthcare policy
----------

Key Takeaways
Lower GLP-1 prices are significant progress—but still high
Transparent cash pricing opens the door to true competition
Safer, regulated brand-name medications should be prioritized over compounded alternatives
Expanded access must be paired with clinician expertise
The GLP-1 moment is exposing—and reshaping—the drug pricing system
Patients deserve care that is safe, evidence-based, and rooted in long-term health
----------

Connect with Dr. Arti Thangudu
Website: https://www.sacomplete.com/
HeyHealthy https://www.heyhealthy.com
Instagram:   / drartithangudu  
Endocrine Matters Podcast